RJA
AMED

Raymond James & Associates’s Amedisys AMED Stock Holding History

Raymond James & Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,780
Closed -$529K – 3794
2023
Q2 		$529K Sell
5,780
-204
-3% -$16.7K ﹤0.01% 2905
2023
Q1 		$440K Sell
5,984
-402
-6% -$34.8K ﹤0.01% 2990
2022
Q4 		$533K Sell
6,386
-1,653
-21% -$149K ﹤0.01% 2858
2022
Q3 		$778K Sell
8,039
-1,396
-15% -$166K ﹤0.01% 2553
2022
Q2 		$992K Sell
9,435
-1,666
-15% -$213K ﹤0.01% 2453
2022
Q1 		$1.91M Buy
11,101
+680
+7% +$102K ﹤0.01% 2161
2021
Q4 		$1.69M Sell
10,421
-6,680
-39% -$1.07M ﹤0.01% 2291
2021
Q3 		$2.55M Buy
17,101
+6,473
+61% +$1.35M ﹤0.01% 1920
2021
Q2 		$2.6M Buy
10,628
+169
+2% +$44.3K ﹤0.01% 1914
2021
Q1 		$2.77M Sell
10,459
-3,874
-27% -$1.09M ﹤0.01% 1804
2020
Q4 		$4.2M Buy
14,333
+152
+1% +$39K ﹤0.01% 1441
2020
Q3 		$3.35M Sell
14,181
-526
-4% -$120K ﹤0.01% 1434
2020
Q2 		$2.92M Buy
14,707
+722
+5% +$135K ﹤0.01% 1496
2020
Q1 		$2.57M Buy
13,985
+6,964
+99% +$1.24M ﹤0.01% 1435
2019
Q4 		$1.17M Buy
7,021
+1,017
+17% +$151K ﹤0.01% 2173
2019
Q3 		$787K Sell
6,004
-1,079
-15% -$140K ﹤0.01% 2330
2019
Q2 		$860K Sell
7,083
-695
-9% -$82.5K ﹤0.01% 2305
2019
Q1 		$959K Buy
7,778
+596
+8% +$74.8K ﹤0.01% 2229
2018
Q4 		$841K Buy
7,182
+3,255
+83% +$384K ﹤0.01% 2186
2018
Q3 		$491K Buy
+3,927
New +$434K ﹤0.01% 2716
2017
Q3 		– Sell
-3,378
Closed -$212K – 3399
2017
Q2 		$212K Buy
+3,378
New +$197K ﹤0.01% 2945

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Raymond James & Associates's AMED Position: Q3 2023 in Review

Raymond James & Associates sold out of Amedisys (AMED) in Q3 2023, closing a stake of 5,780 shares — an estimated $529K sold.

Raymond James & Associates first reported a position in AMED in Q2 2017 and held it in 21 quarters. The position peaked at $4.2M in Q4 2020. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Raymond James & Associates reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 5,780 Amedisys shares in Q3 2023, an estimated $529K.
  • Raymond James & Associates first reported a position in Amedisys in Q2 2017 and held it in 21 quarters.
  • Raymond James & Associates's Amedisys position peaked at $4.2M in Q4 2020.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.